- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
Be careful, though - the company's mergers and partnerships come with risk.
The focus was on new drugs under development and bringing them to market.
Goldman upgrades the early recovery plays; also, gauging Chinese growth and the swine flu effect on pork producers.
Expect a lively Q&A as management finesses the robust pipeline prospects in the face of coming generic exposure.
The stock's impressive rebound makes investors look well into the next decade to justify further gains.